Highlights of the Skin Disease Education Foundation 10th Annual Psoriasis Forum
The first Skin Disease Education Foundation (SDEF) Psoriasis Forum in 2004 focused on the new therapeutic opportunities offered by the relatively new biologic agents—at that time, tumor necrosis factor (TNF) inhibitors. Over the subsequent decade, the scope of the program has grown, now covering all aspects of the diagnosis and treatment of psoriasis. The expanding scope reflects an unmet need for ongoing professional education as the management of this disease continues to increase in complexity. This continuing medical education supplement to Seminars in Cutaneous Medicine and Surgery is based on presentations from the SDEF 10th Annual Psoriasis Forum. It provides a comprehensive overview of the information covered at that conference.
If you would like to complete the CME portion of this supplement, please go to http://www.globalacademycme.com/search/search-result-single/highlights-of-the-skin-disease-education-foundation-10th-annual-psoriasis-forum/c0ab7366269a9f7568b1206bdb3ad503.html.
This continuing medical education supplement to Seminars in Cutaneous Medicine and Surgery is based on presentations from the SDEF 10th Annual Psoriasis Forum. It provides a comprehensive overview of the information covered at that conference.
Psoriasis is now recognized as an immunologically mediated systemic disease that may be expressed in cutaneous and joint symptoms.
This article briefly addresses key issues that can adversely affect the use of and compliance with currently available topical treatments, as well as new and emerging topical agents for psoriasis.
Data on efficacy and adverse effects—particularly hepatoxicity—are reviewed, and recommendations for monitoring are addressed.
This article reviews the most recent evidence on the efficacy and safety of the TNF inhibitors in psoriasis, with special attention to preventing and managing immunogenicity.